Attention-deficit/hyperactivity disorder

Apr 11, 2023

FDA Grants Orphan Drug Designation to Osemitamab for Pancreatic Cancer Transcenta Holding Limited has announced that the U.S. Food and Drug Administration (FDA) has awarded Orphan Drug Designation to Osemitamab (TST001), a highly potent humanized monoclonal antibody that enhances ADCC (antibody-dependent cell-me...

Jun 15, 2022

Over the last decade, various technologies, after being evaluated rigorously, have exhibited competence in treating mental health by becoming an extension of the already present care models. Today, the patient or user can now download a clinical-grade app on the phone, tablet, or computer and use it as a reliable m...

May 03, 2022

FDA Grants Fast Track Designation to VB-111 for Platinium-resistant Ovarian Cancer The FDA has given VBL Therapeutics’ VB-111 (ofranergene obadenovec), a targeted anticancer viral gene therapy, fast track designation for use as a viable therapeutic option in patients with platinum-resistant Ovarian Cancer. VB...

Aug 05, 2020

The Attention deficit/hyperactivity disorder (ADHD) is a complex neurodevelopmental disorder that affects children and teens. ADHD is mostly recognised during the early school years and can also continue into adulthood. ADHD includes symptoms such as inattentiveness, hyperactivity, and impulsiveness. Often referred...

Dec 20, 2018

Attention-deficit/hyperactivity disorder (ADHD) is a brain disorder marked by an ongoing pattern of inattention and/or hyperactivity-impulsivity that interferes with functioning or development. ADHD is a group of behaviors. It is also called as attention deficit disorder (ADD). Attention deficit hyperactivity disor...